Publication number: 20240299334
Abstract: This invention relates to pharmaceutical chemistry and specifically to the pharmaceutical composition of the compounds, which show multi-targeted action on the cholinergic, glutamatergic and mitochondrial systems that are affected in Alzheimer's Disease (AD), whose general Formula (I) is I, wherein the substituents R1 and R2 are set out in the description and claims. The formulation of these compounds increases effectiveness and tolerance in oral, sublingual, parenteral, transdermal and nasal administration. They can be used on their own, as monotherapy, as a replacement of the multi-therapy currently used for AD. The formulation of these compounds, their salts, hydrates, enantiomers, isomers, metabolites, prodrugs for administration to humans, as active ingredients for the treatment of AD, increases bioavailability, residence time of the active ingredient and adequate excretion, which increases the effectiveness, biosafety, adherence and tolerance to the treatment.
Type:
Application
Filed:
November 18, 2021
Publication date:
September 12, 2024
Applicant:
CENTRO DE NEUROCIENCIAS DE CUBA, CNEURO
Inventors:
Chryslaine RODRÍGUEZ-TANTY, Marquiza SABLÓN CARRAZANA, Roberto MENÉNDEZ SOTO DEL VALLE, Alberto BENCOMO MARTÍNEZ, Suchitil RIVERA MARRERO, Laura GARCÍA PUPO, Leonora GONZÁLEZ MESA, Samila LEÓN CHAVIANO, Adriana ÁGUILA CORDOVA, Kathleen CASTRO-PALOMINO ANTELA, Giselle PENTÓN ROL, Laura OTAÑO TAMAYO, Rafaela PÉREZ PERERA, Majel CERVANTES LLANOS, Orestes de Jesús DÍAZ GARCÍA, Miriam DORESTE BROWN